Tenet Healthcare Corporation (THC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates positive sentiment with raised guidance for EBITDA and free cash flow, indicating strong financial performance. The Q&A section revealed management's focus on sustainable expense management and technology adoption, which are positive for long-term growth. While there are concerns about hospital admission growth and Medicaid payments, the overall tone remains optimistic. The company's emphasis on share buybacks and strategic investments further supports a positive outlook. Despite some uncertainties, the raised guidance and strategic initiatives suggest a positive stock price movement in the near term.
Key Financial Performance
Net Operating Revenues (2025) $21.3 billion, representing a 14% growth over 2024. This growth was driven by strong same-store revenue growth, high patient acuity, and disciplined cost control.
Consolidated Adjusted EBITDA (2025) $4.57 billion, a 14% increase over 2024. The adjusted EBITDA margin improved by over 200 basis points to 21.4%, attributed to strong operational performance and cost management.
USPI Adjusted EBITDA (2025) $2.026 billion, a 12% growth over 2024. Same-facility revenues grew 7.5%, driven by double-digit same-store volume growth in total joint replacements in ASCs.
Hospital Segment Adjusted EBITDA (2025) $2.54 billion, a 16% increase over 2024. Same-store revenues per adjusted admission increased by 5.3%, supported by strong payer mix and patient acuity.
Fourth Quarter Net Operating Revenues (2025) $5.5 billion, with consolidated adjusted EBITDA of $1.183 billion, a 13% increase over the same quarter in 2024. Adjusted EBITDA margin for the quarter was 21.4%.
Free Cash Flow (2025) $2.53 billion, supported by strong operational performance and cash collection.
Share Repurchase (2025) 8.8 million shares repurchased for $1.386 billion, reducing outstanding shares by approximately 22% since the program began in Q4 2022.
Leverage Ratio (2025) 2.25x EBITDA or 2.85x EBITDA less NCI, reflecting strong operational performance and financial discipline.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
USPI Adjusted EBITDA: Grew 12% in 2025 to $2.026 billion, with double-digit same-store volume growth in total joint replacements in ASCs.
M&A and De Novo Activity: Invested nearly $350 million in 2025, adding 35 facilities to the portfolio.
Market Expansion in USPI: Continued mix shift towards lower-cost sites of care, with opportunities in high acuity spine and urology procedures due to the phaseout of the inpatient-only list in 2026.
Operational Efficiencies: Achieved 14% growth in consolidated adjusted EBITDA to $4.57 billion in 2025, with a 210 basis point improvement in adjusted EBITDA margin to 21.4%.
Cost Management: Implemented disciplined cost control measures, reducing contract labor expense to 2.1% of consolidated salary, wages, and benefits.
Share Repurchase Program: Retired approximately 22% of outstanding shares for $2.5 billion since Q4 2022.
2026 Guidance: Projected adjusted EBITDA of $4.485 billion to $4.785 billion, with focus on organic growth, M&A, and cost savings to mitigate headwinds from expiration of enhanced premium tax credits.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Expiration of Enhanced Premium Tax Credits: The expiration of enhanced premium tax credits on the exchange marketplace is expected to result in a 20% reduction in overall enrollment, particularly in states like Arizona, Michigan, and California. This could lead to an increase in uninsured rates, negatively impacting the payer mix and hospital segment revenues.
Uncertainty in Enrollment and Coverage: There is uncertainty regarding effectuation rates as individuals determine if they can afford premiums, which could further increase uninsured rates and reduce revenue.
Headwind from Expiration of Tax Credits: The expiration of enhanced exchange tax credits is estimated to have a $250 million impact on 2026 adjusted EBITDA, primarily affecting the hospital segment.
Potential Lower Volume Growth: Lower volume growth and a less favorable payer mix are anticipated due to the expiration of enhanced exchange tax credits, which could impact financial performance.
Dependence on Supplemental Medicaid Programs: The 2026 outlook does not assume contributions from potential increases in supplemental Medicaid programs that have not yet been approved, creating uncertainty in revenue projections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Adjusted EBITDA: Projected to be in the range of $4.485 billion to $4.785 billion, driven by demand, acuity, physician recruitment, service line expansion, and additional sites of care.
USPI Adjusted EBITDA: Expected to be $2.13 billion to $2.23 billion in 2026, supported by a mix shift towards lower-cost sites of care and opportunities in high acuity spine and urology procedures.
Hospital Segment Adjusted EBITDA: Anticipated to range from $2.355 billion to $2.555 billion in 2026, with considerations for the expiration of enhanced premium tax credits and a 20% reduction in overall enrollment.
Same-Store Volume Growth: Expected growth of 1% to 2% in same hospital admissions and adjusted admissions in 2026.
USPI Revenue Growth: Projected same-facility revenue growth of 3% to 6% for 2026.
Capital Expenditures: Planned to be in the range of $700 million to $800 million for 2026, focusing on M&A and organic growth opportunities.
Free Cash Flow: Expected adjusted free cash flow in the range of $2.5 billion to $2.8 billion, with adjusted free cash flow after NCI between $1.6 billion and $1.83 billion.
Revenue Projections: Consolidated net operating revenues for 2026 are expected to range from $21.5 billion to $22.3 billion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Over the past 3 years, Tenet Healthcare has been active in repurchasing shares, retiring approximately 22% of outstanding shares for around $2.5 billion since the program began in Q4 2022. In 2025 alone, the company repurchased 8.8 million shares for $1.386 billion, including 943,000 shares for $198 million in Q4 2025. The company plans to continue deploying capital for share repurchases, particularly at current valuation multiples.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you expand on the same-store hospital volume performance in the quarter and the outlook for hospital volumes in 2026?
A:The acuity was good in Q4, but the respiratory season was weaker than expected. Investments in growth capital during the year are expected to yield returns in 2026, leading to improved performance.
Q:What does tackling expense management more structurally mean, and what are the incremental cost efficiencies expected this year?
A:Structural expense management involves deploying technology for expense reduction, including automation and modernization in clinical throughput areas like length of stay management and high-value hospital areas. This approach is more sustainable and modern compared to traditional methods.
Q:Can you provide more color on the hospital admission growth guide of 1% to 2% and the factors contributing to the slowdown?
A:The slowdown is attributed to factors like exchange expiry, investments in higher acuity and margin capabilities, and a general slowdown in acute sector admissions. A 20% decrease in exchange enrollment is assumed, with some patients potentially becoming uninsured but still utilizing hospital services.
Q:Are you able to quantify the cost efficiencies for this year and their timing?
A:Specific guidance on cost efficiencies is not provided. However, the guidance includes the value of capital and growth strategies as well as structural expense management initiatives aimed at long-term preparation.
Q:Is the growth focus on expense management sustainable in the long term?
A:The company has a track record of margin expansion and aims to prepare for future challenges. The focus on expense management is seen as a necessary step to sustain growth and adapt to upcoming changes in the healthcare environment.
Q:What is the broader technology agenda, including AI, and its impact on margins?
A:The company is leveraging AI and automation to drive efficiencies and margin improvements. Standardized processes and workflows have been established, enabling the deployment of new technologies to achieve the next level of improvement.
Q:Can you provide details on the guidance for Medicaid supplemental payments and the impact of subsidy expirations?
A:The 2025 Medicaid supplemental payments totaled $1.34 billion, with a normalized baseline of $1.2 billion for 2026. A 20% reduction in exchange enrollment is assumed, with 10%-15% of enrollees expected to find alternative plans.
Q:Why is the first quarter guidance for EBITDA lower than usual?
A:The lower guidance is due to a $40 million prior period DPP benefit in Q1 2025. Other than this, the annual Q1 percentages are consistent with historical trends.
Q:What is the plan for Conifer services after the CommonSpirit contract concludes?
A:The company plans to redeploy resources to growth opportunities and reduce expenses to rightsize the cost structure. The transaction with CommonSpirit created significant value, including $1.9 billion in accelerated cash flow and a $1 billion to $1.1 billion after-tax NPV benefit.
Q:What are the investment plans for the ASC business and the opportunities for growth?
A:The ASC business focuses on higher acuity procedures, robotics, and joint programs. Recent acquisitions will undergo service line diversification and physician entry planning. GI case recovery also contributed to Q4 performance.
Q:What were the exchange volumes and revenues in Q4, and what is the status of Medicaid supplemental program approvals?
A:Exchange volumes accounted for 7.5% of total admissions and 6.5% of consolidated revenues in Q4. No updates are available on pending Medicaid supplemental program approvals.
Q:What is the outlook for managed care contracting and rates?
A:Managed care contracting remains positive, with rates in the 3%-5% range. The company is highly contracted for 2026 and 2027, ensuring stability in payer relationships.
Q:What changes in payer mix were observed in Q4, and what is expected for 2026?
A:The payer mix for USPI remained consistent, with GI case recovery slightly affecting the mix. The guidance range for 2026 is broader due to uncertainties in payer mix changes.
Q:How much of the ambulatory segment's payer mix came from ACA exchanges, and was there any pull forward in Q4?
A:The company does not disclose specific payer mix details for the ambulatory segment but noted that ACA exchange exposure is significantly less than the hospital segment. No significant pull forward was observed in Q4.
Q:What is the company's position on coding practices and disputes with payers?
A:The company maintains compliant and accurate coding practices, with no significant changes in recent years. Disputes with payers are more related to denials and underpayments rather than coding practices.
Q:What is the approach to share buybacks given the current valuation and financial position?
A:The company views share buybacks as an attractive use of capital, given its strong balance sheet, free cash flow generation, and confidence in its operational performance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on cost efficiencies for the year, the timing of these efficiencies, and the payer mix changes expected in 2026. Additionally, no updates were given on the approval status of pending Medicaid supplemental programs.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASCs term
Arizona Michigan
California uncertainty
Commission Saum
Hospital segment
Michigan California
Mr Vice
Saum revenue
USPI capital
USPI mix
USPI strength
USPI year
Volumes facility
ability core
access care
acquirer developer
activity line
acuity capability
acuity physician
acuity spine
anticipation year
area acuity
asset space
beginning phaseout
business Hospital
business momentum
capability capital
capability patient
capital return
capital share
capital year
de novo
enrollment
individual
portfolio business
share repurchase
site care
THC Transcript
Tenet Healthcare Corporation (THC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Tenet Healthcare Corporation (THC) Q1 2026 Earnings Call Transcript
Unknown4-30
The earnings call summary shows mixed results. Basic financial performance is stable, but no year-over-year growth in key metrics. Product development is positive with high-acuity service growth. Market strategy is stable, with successful M&A but no groundbreaking changes. Expenses are managed well, but concerns about payer denials and Medicaid trends persist. Shareholder returns are positive with share repurchases. Q&A insights reveal stable but unimproved payer dynamics and some strategic successes, balancing out the lack of strong guidance changes. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Tenet Healthcare Corporation (THC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
Tenet Healthcare Corporation (THC) Q4 2025 Earnings Call Transcript
Positive2-11
The earnings call summary indicates positive sentiment with raised guidance for EBITDA and free cash flow, indicating strong financial performance. The Q&A section revealed management's focus on sustainable expense management and technology adoption, which are positive for long-term growth. While there are concerns about hospital admission growth and Medicaid payments, the overall tone remains optimistic. The company's emphasis on share buybacks and strategic investments further supports a positive outlook. Despite some uncertainties, the raised guidance and strategic initiatives suggest a positive stock price movement in the near term.
THC Slides
THC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
